Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
09/2003
09/25/2003WO2003078404A1 Pyrimidine derivatives
09/25/2003WO2003078402A1 Indazoles substituted with an anti-cancerous activity
09/25/2003WO2003078401A1 Preventive and/or therapeutic agent for hypoxic ischemic brain disorder
09/25/2003WO2003078400A1 Neurotensin active 2,3-diaryl-pyrazolidine derivatives
09/25/2003WO2003078395A1 Piperidine derivatives useful as modulators of chemokine receptor activity
09/25/2003WO2003078376A1 Nk1 antagonists
09/25/2003WO2003078361A1 Controlling chemical reactions by spectral chemistry and spectral conditioning
09/25/2003WO2003077999A1 Combination ofa cdk inhibitor and 5-fu for the treatment of cancer
09/25/2003WO2003077998A1 Use of asc-1 inhibitors to treat neurological and psychiatric disorders
09/25/2003WO2003077965A1 Polymer composition loaded with cells
09/25/2003WO2003077949A2 Methods of treating diabetes using pde 11a inhibitors
09/25/2003WO2003077947A1 Methods of modulating cd200 receptors
09/25/2003WO2003077935A1 Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase iv activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states
09/25/2003WO2003077927A1 Sulfatase inhibiting progestogen-only contraceptive regimens
09/25/2003WO2003077926A1 Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
09/25/2003WO2003077924A1 Continuous sulfatase inhibiting progestogen hormone replacement therapy
09/25/2003WO2003077920A1 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo’1,5-bipyridazine in nanoparticulate form
09/25/2003WO2003077919A1 Fluorinated 4-azasteroid derivatives as androgen receptor modulators
09/25/2003WO2003077916A1 Use of proton pump inhibitors for the treatment of noncardiac chest pain
09/25/2003WO2003077915A1 Use of rapamycin for inhibiting of cell death
09/25/2003WO2003077914A1 N3 alkylated benzimidazole derivatives as mek inhibitors
09/25/2003WO2003077910A1 Methods of treatment with selective ep4 receptor agonists
09/25/2003WO2003077908A1 Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
09/25/2003WO2003077907A1 Azetidine derivatives as ccr-3 receptor antagonists
09/25/2003WO2003077906A1 Cyclic etheramine derivatives as medicaments for malignant tumors
09/25/2003WO2003077904A1 Biological activity-promoting compositions containing soybean germ-origin isoflavone aglycon
09/25/2003WO2003077893A2 Compositions for treating digestive functional pathologies
09/25/2003WO2003077892A2 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for treating ang ii-mediated diseases
09/25/2003WO2003077862A2 Potent, simplified derivatives of immunosuppressive agents
09/25/2003WO2003077857A2 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
09/25/2003WO2003077850A2 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
09/25/2003WO2003077834A2 Central airway administration for systemic delivery of therapeutics
09/25/2003WO2003070738A3 Topiramate salts and compositions comprising and methods of making and using the same
09/25/2003WO2003047552A3 Pharmaceutical composition comprising a 5ht1 receptor agonist
09/25/2003WO2003045434A3 Endothelin antagonists ina method and composition for potentiating an opiate analgesic
09/25/2003WO2003042246A3 Inhibitors of the notch signalling pathway for use in the treatment of cancer
09/25/2003WO2003042245B1 Growth hormone variations in humans and their uses
09/25/2003WO2003039472A3 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
09/25/2003WO2003039451A3 Thiazole pyridazinones as adenosine antagonists
09/25/2003WO2003035879A3 Promoters to control cell differentiation
09/25/2003WO2003035682A3 Peptides and protins binding to glu-pro motidfs, therapeutical compositions containing them and their applications
09/25/2003WO2003020219A3 Aerosolized decongestants for the treatment of sinusitis
09/25/2003WO2003013577A3 Use of il-18 inhibitors in hypersensitivity disorders
09/25/2003WO2003013537A3 Irinotecan for treatment of cancer
09/25/2003WO2003013535A3 Use of irinotecan for improved treatment of cancer based on mdr1
09/25/2003WO2003013530A3 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists
09/25/2003WO2003011855A3 Pyrazole-derived kinase inhibitors and uses thereof
09/25/2003WO2003007924A3 Combinations comprising epothilones and pharmaceutical uses thereof
09/25/2003WO2003002114A3 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
09/25/2003WO2003002108A3 Use of tyrosine kinase inhibitors for treating inflammatory diseases
09/25/2003WO2003000709A3 Sialic acid derivatives for use as siglec inhibitors
09/25/2003WO2002100827A9 Method for increasing the survival of dopamine secreting cells
09/25/2003WO2002100818A3 Aminediols as agents for the treatment of alzheimer's disease
09/25/2003WO2002096357A3 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
09/25/2003WO2002092826A3 Composition and method for treating cancer using herpes virus
09/25/2003WO2002080911A3 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments for the treatment of neurodegenerative diseases
09/25/2003WO2002077263A3 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
09/25/2003WO2002076482A3 USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS
09/25/2003WO2002074733A3 Tryptase-inhibitors
09/25/2003WO2002064612A9 Human g-protein chemokine receptor (ccr5) hdgnr10
09/25/2003WO2002063004A3 G-protein coupled receptors
09/25/2003WO2002055688A8 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
09/25/2003WO2002046419A3 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
09/25/2003WO2002036573B1 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
09/25/2003WO2002032842A3 Compounds with high monoamine transporter affinity
09/25/2003WO2002031146A3 Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof
09/25/2003WO2002030884A3 Sulfide and disulfide compounds and compositions for cholesterol management and related uses
09/25/2003WO2002028355A3 Methods and compositions for enhancing angiogenesis
09/25/2003WO2002026982A3 Secreted human proteins
09/25/2003WO2002024910A3 Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof
09/25/2003WO2002020846A3 Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure
09/25/2003US20030182668 Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
09/25/2003US20030181766 Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them
09/25/2003US20030181728 Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
09/25/2003US20030181716 Novel azepane derivatives
09/25/2003US20030181714 Oligosaccharide chain, which contianing a terminal NeuNAc alpha 6 linked to a linear or branched polylcatosamine type structure containing at least 3 lactosamine; a linear or branched structure with two lactosamine and one lactose
09/25/2003US20030181689 Percarboxylated polysaccharides, and a process for their preparation
09/25/2003US20030181687 Heparanase activity neutralizing anti-heparanase monoclonal antibody
09/25/2003US20030181658 Exhibit protease activity as a single chain or as an activated two chain form; use of polypeptides to identify compounds that modulate the protease activity thereof and as tumor markers
09/25/2003US20030181587 Thermoplastic resin composition
09/25/2003US20030181518 Compositions and methods for treating cystic fibrosis
09/25/2003US20030181512 For therapy and prophylaxis of obesity and hyperlipidemia; side effect reduction
09/25/2003US20030181508 For therapy of attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder
09/25/2003US20030181507 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
09/25/2003US20030181506 Hetercyclic carboxy compounds such as alpha-methyl-2-naphthalene-methyl 2-(4-fluorophenoxy)-5-oxotetrahydrofuran-2-carboxylate used to selectively regulate induction of cytotoxic effecter macrophages
09/25/2003US20030181502 Methods of treating sepsis
09/25/2003US20030181500 For therapy and prophylaxis of cardiac failure, the prevention of ischemic coronary heart disease or recurrence of ischemic coronary heart disease
09/25/2003US20030181498 For therapy of disease mediated by interation of Vascular Cell Adhesion Molecule-1 (VCAM-1) and/or fibronectin and integrin receptor and/or alpha 4 beta 1
09/25/2003US20030181497 Heterocyclic acridone inhibitors of IMPDH enzyme
09/25/2003US20030181491 C2-disubstituted indan-1-ol compounds, their derivatives, processes for their preparation, and their use as pharmaceuticals
09/25/2003US20030181490 For therapy and prophylaxis of acquired immune deficiency syndrome (AIDS), or ARC
09/25/2003US20030181481 Therapeutic drugs for treating central nervous system disorders
09/25/2003US20030181480 Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds
09/25/2003US20030181477 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
09/25/2003US20030181476 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
09/25/2003US20030181474 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents
09/25/2003US20030181473 Farnesyl protein transferase inhibitor combinations with taxane compounds
09/25/2003US20030181471 Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-YI)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders
09/25/2003US20030181464 Phenylsulphonylipiperazinyl derivatives as 5-ht receptor ligands
09/25/2003US20030181459 Use of a vitamin combination for the treatment of primary headaches
1 ... 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 ... 1564